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IT has been reported that the growth ofsome transplanted tumours in mice and
rats may be inhibited by prior treatment of the host by various agents which are
known to stimulate the phagocytic activity of the reticulo-endothelial system,
including zymosan (Bradner, Clarke and Stock, 1958), living Mycobacteriu.n
tuberculosis (strain BCG) (Biozzi et al., 1959; Old, Clarke and Benacerraf, 1959;
Halpern et al., 1959; Halpern, Biozzi and Stiffel, 1963), and a bacterial extract
Halpern et al., 1963).
In the experiments cited above the tumours were capable ofgrowing in various
strains and were transplanted to animals non-isogeneic with those in which they
had originated ; it is, therefore, impossible to assess the significance of the results
from the point of view of tumour immunology. This criticism does not apply,
however, to the work ofWeiss, Bonhag and De Ome (1961), who studied the effect
ofprior infection with living BCG. injection ofphenol-killed BCG, and injection of
methanolic extracts of BCG and their residues on the behaviour of five recent
mouse tumours transplanted within the strain of origin. They observed various
types of effect in the treated animals, including (a) initial retardation of tumour
development followed by normal rate of growth, (b) persistent retardation of
growth rate, (c) complete prevention of tumour development, (d) initial tumour
development followed by regression, (e) inhibition of metastatic spread, and (f )
prolonged survival of animals which did develop massive tumours. At certain
dose levels some non-living preparations were as effective as, or even more effective
than, living BCG, but excessive quantities, even though considerably below the
threshold of gross toxicity, sometimes accelerated tumour development. With
some preparations treatment three months and one month before tumour trans-
plantation were equally effective.
The present experiments resemble those of Weiss et at. (1961) in that the
tumours studied were transplanted in mice isogeneic with the mouse in which the
particular tumour originated, but differ in the following respects:
1. Injection of killed Corynebacterium parvum was used in place of BCG as a
means of reticulo-endothelial stimulation. It has been shown by Halpern,
Prevot, Biozzi, Stiffel, Mouton, Morard, Bouthillier and Decreuesefond (1964)
that single or repeated injection of this agent causes intense stimulation of the
lymphoreticular tissues, and recently Biozzi, Howard, Mouton and Stiffel (1965)
have reported that it is even more effective than BCG in reducing the mortality
from graft-versus-host disease when (C57B1/6 x C3H/He)F1 hybrid mice are
injected with parent line C57B1/6 spleen cells. The mechanism of the protectiveM. F. A. WOODRUFF AND J. L. BOAK
effect observed by Biozzi et al. is uncertain, but these authors suggest that it is
probably due to stimulation of lymphoreticular tissue and consequent increased
non-specific resistance to infection.
2. The tumours were transplanted in the form of suspensions containing a
measured number of viable cells, and various dose levels were employed.
3. The treatment designed to stimulate reticulo-endothelial activity was giveen
either 2 days before or some time after tumour inoculation.
MATERIALS AND METHODS
General plan of the investigation
Two experiments were performed. In both, mice received a subcutaneous
injection of cells derived from a tumour which had originated in a mouse of the
same genetic constitution. Some of the recipients were kept as untreated coIn-
trols; others received an intravenous injection of killed C. parvum (0.5 mg. wet
weight) either 2 days before or 8 or 12 days after the tumour inoculation. Details
of the mice and tumours used in each experiment are shown below:
Experiment 1. Host mice: A-strain females.
Tumour: First generation transplant of a mammary
carcinoma which had originated spon-
taneously in an A-strain female.
Experiment 2. Host mice: (CBA x A)F1 females.
Tumour: Sarcoma induced by subcutaneous injection
of methylcholanthrene in a (CBA x A)F1
female.
The mice were inspected twice weekly and if a tumour was present measure-
ments were made with a caliper in its long axis and in a direction perpendicular to
this. The arithmetic mean of these two measurements was taken as the mean
tumour diameter. Tumours ofdiameter less than 5 mm. were recorded as palpable
(P); in calculating group means this has been taken as equivalent to a mean
tumour diameter of 2*5 mm.
Mice.-The mice were bred in the Department of Surgical Science, University,
of Edinburgh. The parent strains are checked regularly for uniformity by
intrastrain skin grafting.
Corynebacterium parvum. The anaerobic strain 936B was used as described
by Halpern et al. (1964). Cultures were sterilised by heating to 65° C. for 1 hour
and preserved in 0.2 per cent formalin. This material was kindly supplied by
Professor Halpern. Injections were made i.v.
Tumour cell suspensions. Tumour cell suspensions were prepared by a modifi-
cation of the method described by Boyse (1960). The procedure takes only 2."
hours as compared with 4 hours for Boyse's original method, gives a higher yield of
viable cells as judged by their failure to stain with trypan blue (approximately
120 106 viable cells per g. wet weight tumour with either the mammary carcinoma
or the methylcholanthrene induced sarcoma, and less than 20 per cent* non-viable
cells), and provides a concentrated suspension in which there is remarkably little
* In 15 successive sarcoma suspensions the proportion of non-viable cells ranged from 4 to 10
per cent. With the mammary carcinoma the proportion ofnoni-viable cells was a little higher, rangiing
from 13 to 20 per cent in 6 successive preparations.
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clumping and which can be diluted as required. In view of these considerable
advantages the procedure will be described in detail.
1. The tumour is excised and placed in a sterile Petri dish containing a few ml.
of sterile Dulbecco's solution (Oxoid) ; all necrotic looking tissue is cut away and
discarded, and the remainder is cut into small pieces (2-4 mm.) with a pair of
scalpels (No. 11 blades).
2. The pieces of tumour are transferred to a Melnick flask, washed twice with
Dulbecco solution, covered with warmed (370 C.) " Pronase-Dulbecco "* to which
has been added 2 drops of Dnase-1 solution (Deoxyribonuclease 1. Sigma London
Chemical Co. Ltd.), and incubated in a water bath at 37° C. for 30 minutes. The
Dnase-I solution is prepared at a concentration of 0.2 mg. Dnase-I per ml. Dul-
becco's solution and stored in 2 ml. ampoules at -20° C.
3. The supernatant is poured off and discarded, more Pronase-Dulbecco
and Dnase solution is added, and incubation is continued for a further 10 minutes,
this time with gentle magnetic stirring.
4. The supernatant (which constitutes the first yield of cell suspension) is
decanted through 2-ply sterile gauze into a cold Erlenmeyer flask surrounded by
crushed ice.
5. Steps 3 and 4 are repeated twice, and each time the supernatant is added to
the cell suspension already harvested.
6. The suspension is strained through stainless steel mesh into cold polypro-
pylene centrifuge tubes. The cells are spun down (310 g. for 10 minutes), washed
once in cold 0.15 M NaCl and resuspended in Dulbecco's solution containing a
few drops of Dnase solution.
7. The suspension is again strained through stainless steel mesh, counted, and
diluted with Dulbecco's solution to give the required cell concentration.
RESULTS
The experimental protocols are set out in Tables I and II, and the findings are
summarised in Fig. 1-3.
In analysing the data it has seemed desirable to examine the effect of both
tumour cell dosage and treatment with C. parvum on the proportion of animals in
which the tumour takes, the time of first appearance of the tumour in animals in
which it does take, the pattern of growth after the tumour has become palpable,
and the length of survival of the tumour recipient.
Examination ofthe growth curves forindividual mice (which are notreproduced
but can be constructed from the tables) shows that with both tumours, as a general
rule, there was a period lasting some weeks (referred to hereafter as the phase of
linear diametric growth) during which the tumour diameter increased in an
approximately linear manner with time, after which the growth rate slackened off.
It is not possible from the data to determine the form of the growth curve before
the beginning of the phase of linear diametric growth because the tumours were
too small to be measured, and the other end ofthe curve is oflittle interest because
* Prepared as follows: To 1000 nml. Dulbecco's solution add, in order, 2-5 g. Pronase (Californian
C'orporation for Biochemical Research, Los Angeles), 500,000 units penicillin, 05 g. streptomycin,
0-2 g. neomycin, 5 ml. 0-4 per cent phenol red solution. Adjust pH to 7 2 with 10 per cent NaOH
and store unsterilized at -20' C. Thaw in 37° C. water bath the day before use and sterilize by
filtration through HA millipore. The sterile material is stored at 4° C. for up to a week and if not
used is then (liscardecl.
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FIG. 1.-Experiment 1. Graph of tumour mean diameter plotted against time. All mice
received 1 x 105 viable mammary carcinoma cells on Day 0.
*-- Controls-no treatment.
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FIG. 2.-Experiment 1. Graph of tumour mean diameter plotted against time. All mice
received 1 x 104 viable mammary carcinoma cells on Day 0.
I_-__ 4 Controls-no treatment.
- - - Q -5 mg. C. parvum i.v. Day - 2.
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during the terminal phase of growth the tumours began to ulcerate through the
skin. In comparing different experimental categories, therefore, it has seemed
appropriate, after considering separately the mice in which the tumour failed to
take, to compare the group mean tumour diameters at two different times, one
towards the beginning ofthe phase oflinear diametric growth and the othertowards
its end (Table III). For this purpose we have used a modified t-test (Bailey, 1959),
which gives a valid comparison of the means of two small samples even if the
variances of the populations from which they are drawn differ significantly.
Trne-days
Fic. 3.-Experiment 2. Graph of tumour moan diameter plottedl against time. Mice received.
stated dose of viable sarcoma cells on Day 0.
1 x 105 Sarcoma cells s.c.
Controls.
1 X 104 Sarcoma cells s.c.
Controls.
I X 103 Sarcoma cells s.c.
Controls.
1 x 102 Sarcoma cells s.c.
Controls.
*_--- -_ 1 x 105 Sarcoma cells s.c.
4- 0 5 mg. C. parvurn i.v. Day -
X_
_ X I X 104 Sarcorna cells s.c.
+ 0 5 mg. C.parvum/ i.v. Day
0---- - 0 1 X 103 Sarcoma cells s.c.
+ 0 5 mg. C. parvunm i.v. Day -
]-- - - -<C 1 x 102 Sarcoma cells s.c.
+ p-5 mg. C. parcu t, i.v. Day
No attempt has been made to attach a definite value to the time offirst appear-
ance of the tumours in individual mice, or even to calculate a mean value for
each experimental group, although this could be done by extrapolating the growth
curve backwards to some arbitrarily chosen small size, because comparisons based
on such estimates are likely to be misleading when the differences are small and
offer no advantage when they are large.
Experiment 1. Mammary carcinoma in female ntice
It will be seen that after a dose of 105 cells the tumour took in all the untreated
mice and thereafter grew in the manner described above. At a dose level of 104
cells in untreated mice one animal failed to develop a tumour. In the remainder
appearance of the tumour was delayed, but once the tumour became palpable its
diameter increased at much the same rate as in mice which received 105 cells.
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The mice which developed tumours following injection of 104 cells survived
significantly longer than those which received 105 cells (f= 3, d = 3-23, P < 0.05).
Treatment with C. parvum either before or after tumour inoculation at either
cell dose level consistently delayed the appearance of the tumour, but had little
or no influence on the rate of increase of diameter after the tumour had become
palpable. Roughly speaking, the tumour behaved similarly in treated mice which
received 105 cells and in untreated mice which received 104 cells. At the higher
dose level it made no difference whether the treatment was given on Day -2 or
Day +8; at the lower dose level there is a suggestion that treatment on Day -2
was more effective than treatment on Day +12, but further observations would be
required before reaching a definite conclusion about this
At the 105 cell dose level survival of the treated animals was significantly
longer than that ofthe controls (f = 13, d = 3*43, P = 0.01); at the 104 level the
comparison is obscured by the failure ofthe tumour to take in 3 mice, but there is
at least a suggestion that treated tumour bearing animals tend to survive longer
than untreated ones.
Experiment 2. Cholanthrene-induced sarcoma
Injection of 105, 104 or 103 cells consistently produced tumours in both control
and treated mice, but in general the smaller the cell dose the longer the interval
before the tumour appeared. Injection of 102 cells produced tumours in just over
half the mice.
Pre-treatment with C. parvum delayed the appearance of the tumour in mice
which received 105 or 104 cells. With smaller tumour cell doses treatment had no
effect on the time of appearance of the tumour or its subsequent growth, though
at the 103 dose level the treated mice survivedsignificantlylongerthanthe controls
(f= 10, d = 2*79, P = 0.02).
DISCUSSION
The experiments reported provide further evidence that the growth of recent
tumours transplanted to mice isogenic with the animal in which the tumour ori-
ginated may be inhibited by treating the host with an agent which is known to be a
powerful stimulant of the reticulo-endothelial system. They show further that
this inhibition may occur even ifadministration ofthe agent in question is delayed
until 8 or 12 days after tumour inoculation. These findings thus support and
extend the work of Weiss et al. (1961).
It seems likely that injection of C. parvum, like parasitisation with BCG,
modifies the immunological reactivity of the treated animal in a complex way,
but until its effects have been more accurately delineated it is idle to speculate
about the mechanism of tumour inhibition. It is of interest, however, that the
effect appeared to be greater with the mammary carcinoma than with the sarcoma,
in view of the fact that chemically-induced sarcomas in general possess easily
demonstrable tumour-specific antigens whereas evidence of the existence of
tumour-specific antigens in spontaneous mouse mammary tumours is indirect
(Woodruff and Symes, 1962) and far from universally accepted.
It should be ofinterest to study the effect ofrepeated inoculation ofC. parvum
on tumour growth since, according to Biozzi (cited Biozzi et al., 1965; as Biozzi,
unpublished data), repeated inoculation of C. parvum is able to restimulate the
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reticulo-endothelial system of mice pretreated with the same organism, whereas
mice re-injected with BCG at the end of the phase of reticulo-endothelial stimula-
tion produced by a prior injection ofBCG show little or no further hyperphagocytic
activity. Experiments along these lines are in progress.
SUMMARY
It has been reported by Halpern et al. that injection of killed C. parvum
causes intense stimulation of lymphoreticular tissue. Experiments were per-
formed to determine the effect of this agent on the growth of transplants of a
spontaneous mammary carcinoma and a methylcholanthrene-induced sarcoma in
mice isogenic with the animal in which the tumour originated.
It was found that i.v. injection of0O5 mg. wet weight ofC. parvum either 2 days
before or 8-12 days after subcutaneous inoculation of 105 or 104 viable mammary
carcinoma cells significantly delayed the appearance of tumour, which occurred at
approximately the same time in treated animals which received 105 tumour cells
as in untreated animals which received 104 cells. Once the tumour had become
palpable however the rate of growth was much the same in treated and untreated
animals.
Injection ofC. parvum also delayed the appearance ofa palpable tumour follow-
ing subcutaneous inoculation of 105 or 104 viable sarcoma cells, but the effect was
less marked than with the mammary tumour.
The method of preparing the cell suspensions, which yielded 90-96 per cent of
viable sarcoma cells and 80-87 per cent of viable carcinoma cells, is described in
detail.
This work has been supported by generous grants from the British Empire
C1ancer Campaign for Research for which grateful acknowledgment is made.
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